Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PSMD10

Gene summary for PSMD10

Gene summary.

Gene information	Species	Human
	Gene symbol	PSMD10
	Gene ID	5716
	Gene name	proteasome 26S subunit, non-ATPase 10
	Gene Alias	dJ889N15.2
	Cytomap	Xq22.3
	Gene Type	protein-coding
	GO ID	GO:0000079
	UniProtAcc	O75832

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
5716	PSMD10	LZE4T	Human	Esophagus	ESCC	2.26e-10	4.22e-01	0.0811
5716	PSMD10	LZE7T	Human	Esophagus	ESCC	1.35e-11	9.05e-01	0.0667
5716	PSMD10	LZE8T	Human	Esophagus	ESCC	9.59e-05	2.11e-01	0.067
5716	PSMD10	LZE20T	Human	Esophagus	ESCC	9.57e-09	3.39e-01	0.0662
5716	PSMD10	LZE22D1	Human	Esophagus	HGIN	4.15e-06	2.44e-01	0.0595
5716	PSMD10	LZE22T	Human	Esophagus	ESCC	9.15e-05	2.99e-01	0.068
5716	PSMD10	LZE24T	Human	Esophagus	ESCC	7.98e-36	1.08e+00	0.0596
5716	PSMD10	LZE6T	Human	Esophagus	ESCC	1.81e-10	8.56e-01	0.0845
5716	PSMD10	P1T-E	Human	Esophagus	ESCC	1.45e-07	7.82e-01	0.0875
5716	PSMD10	P2T-E	Human	Esophagus	ESCC	9.17e-57	9.32e-01	0.1177
5716	PSMD10	P4T-E	Human	Esophagus	ESCC	1.09e-31	6.83e-01	0.1323
5716	PSMD10	P5T-E	Human	Esophagus	ESCC	1.51e-15	3.84e-01	0.1327
5716	PSMD10	P8T-E	Human	Esophagus	ESCC	5.10e-39	6.00e-01	0.0889
5716	PSMD10	P9T-E	Human	Esophagus	ESCC	3.30e-15	4.36e-01	0.1131
5716	PSMD10	P10T-E	Human	Esophagus	ESCC	1.92e-25	5.77e-01	0.116
5716	PSMD10	P11T-E	Human	Esophagus	ESCC	8.48e-10	5.90e-01	0.1426
5716	PSMD10	P12T-E	Human	Esophagus	ESCC	9.91e-26	4.24e-01	0.1122
5716	PSMD10	P15T-E	Human	Esophagus	ESCC	1.64e-23	4.84e-01	0.1149
5716	PSMD10	P16T-E	Human	Esophagus	ESCC	2.20e-30	5.48e-01	0.1153
5716	PSMD10	P17T-E	Human	Esophagus	ESCC	4.45e-09	5.29e-01	0.1278

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004217629	Skin	cSCC	regulation of protein catabolic process	198/4864	391/18723	6.03e-26	1.89e-23	198
GO:004316128	Skin	cSCC	proteasome-mediated ubiquitin-dependent protein catabolic process	205/4864	412/18723	1.46e-25	4.16e-23	205
GO:190336229	Skin	cSCC	regulation of cellular protein catabolic process	139/4864	255/18723	2.06e-22	4.17e-20	139
GO:200123329	Skin	cSCC	regulation of apoptotic signaling pathway	173/4864	356/18723	2.25e-20	3.44e-18	173
GO:190305029	Skin	cSCC	regulation of proteolysis involved in cellular protein catabolic process	121/4864	221/18723	6.75e-20	1.01e-17	121
GO:006113629	Skin	cSCC	regulation of proteasomal protein catabolic process	106/4864	187/18723	4.31e-19	5.87e-17	106
GO:190332029	Skin	cSCC	regulation of protein modification by small protein conjugation or removal	125/4864	242/18723	9.50e-18	1.05e-15	125
GO:003243429	Skin	cSCC	regulation of proteasomal ubiquitin-dependent protein catabolic process	80/4864	134/18723	1.54e-16	1.49e-14	80
GO:200005829	Skin	cSCC	regulation of ubiquitin-dependent protein catabolic process	92/4864	164/18723	2.30e-16	2.12e-14	92
GO:004586229	Skin	cSCC	positive regulation of proteolysis	169/4864	372/18723	2.43e-16	2.21e-14	169
GO:000989628	Skin	cSCC	positive regulation of catabolic process	206/4864	492/18723	6.06e-15	4.64e-13	206
GO:003139629	Skin	cSCC	regulation of protein ubiquitination	107/4864	210/18723	7.17e-15	5.35e-13	107
GO:190336429	Skin	cSCC	positive regulation of cellular protein catabolic process	85/4864	155/18723	1.87e-14	1.31e-12	85
GO:003133128	Skin	cSCC	positive regulation of cellular catabolic process	182/4864	427/18723	3.29e-14	2.22e-12	182
GO:004573229	Skin	cSCC	positive regulation of protein catabolic process	112/4864	231/18723	1.37e-13	8.40e-12	112
GO:190180025	Skin	cSCC	positive regulation of proteasomal protein catabolic process	66/4864	114/18723	5.18e-13	3.01e-11	66
GO:190305225	Skin	cSCC	positive regulation of proteolysis involved in cellular protein catabolic process	72/4864	133/18723	4.24e-12	2.27e-10	72
GO:007233129	Skin	cSCC	signal transduction by p53 class mediator	83/4864	163/18723	7.71e-12	4.00e-10	83
GO:003243625	Skin	cSCC	positive regulation of proteasomal ubiquitin-dependent protein catabolic process	53/4864	90/18723	4.06e-11	1.96e-09	53
GO:200123429	Skin	cSCC	negative regulation of apoptotic signaling pathway	101/4864	224/18723	4.17e-10	1.70e-08	101

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PSMD10

SNV

Missense_Mutation

novel

c.140N>T

p.Ala47Val

p.A47V

O75832

protein_coding

deleterious(0.02)

probably_damaging(0.983)

TCGA-AO-A1KS-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

PSMD10

SNV

Missense_Mutation

c.475C>A

p.Leu159Met

p.L159M

O75832

protein_coding

deleterious(0.02)

possibly_damaging(0.887)

TCGA-FU-A3HZ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

PSMD10

SNV

Missense_Mutation

novel

c.352N>G

p.Arg118Gly

p.R118G

O75832

protein_coding

tolerated(0.08)

benign(0.084)

TCGA-AA-3949-01

Colorectum

colon adenocarcinoma

Female

>=65

III/IV

Unknown

PSMD10

SNV

Missense_Mutation

novel

c.175N>G

p.Leu59Val

p.L59V

O75832

protein_coding

deleterious(0)

probably_damaging(0.978)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

PSMD10

SNV

Missense_Mutation

novel

c.671N>G

p.Val224Gly

p.V224G

O75832

protein_coding

deleterious(0.01)

benign(0.026)

TCGA-A5-A2K5-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

PSMD10

SNV

Missense_Mutation

novel

c.424N>A

p.Ala142Thr

p.A142T

O75832

protein_coding

deleterious(0)

benign(0.14)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

PSMD10

SNV

Missense_Mutation

novel

c.239N>T

p.Ala80Val

p.A80V

O75832

protein_coding

deleterious(0)

probably_damaging(0.984)

TCGA-AX-A0J1-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

PSMD10

SNV

Missense_Mutation

novel

c.466N>A

p.His156Asn

p.H156N

O75832

protein_coding

tolerated(0.22)

benign(0.023)

TCGA-B5-A0JY-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

PSMD10

SNV

Missense_Mutation

novel

c.657A>G

p.Ile219Met

p.I219M

O75832

protein_coding

tolerated(0.29)

benign(0.01)

TCGA-B5-A3FA-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

PSMD10

SNV

Missense_Mutation

c.462G>T

p.Met154Ile

p.M154I

O75832

protein_coding

tolerated(1)

benign(0.001)

TCGA-BS-A0UV-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
5716	PSMD10	TRANSCRIPTION FACTOR BINDING	inhibitor	BORTEZOMIB	BORTEZOMIB
5716	PSMD10	TRANSCRIPTION FACTOR BINDING	inhibitor	CARFILZOMIB	CARFILZOMIB

Page: 1